Rhythm Pharmaceuticals ^{Priced, Nasdaq: RYTM}

We are a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for treatments of the genetic deficiencies that result in metabolic disorders. Our lead product candidate is setmelanotide, a melanocortin-4 receptor, or MC4R agonist for the treatment of obesity that has the potential to serve as a replacement therapy for the treatment of monogenic MC4 pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which in turn, leads to intense feelings of hunger and to obesity. Our development efforts are initially focused on obesity related to six single gene-related, or monogenic, MC4 deficiencies for which there are currently no effective or approved treatments.